As prevention trials for Alzheimer’s disease ramp up, researchers need fast and cheap ways to diagnose early, and to screen cognitively normal people. PET is expensive. Cerebrospinal fluid (CSF) ...
Despite extensive use of biomarkers in research studies, most Alzheimer’s disease diagnoses in the United States are determined by clinical examination. That may be about to change. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results